Sol-Gel Technologies (SLGL) Assets (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Assets of $29.9 million for Q4 2025, down 16.54% year-over-year from $35.8 million in Q4 2024, and down 13.51% on a QoQ basis from $34.6 million in Q3 2025.
Sol-Gel Technologies (SLGL) has 10 years of Assets data on file, last reported at $29.9 million in Q4 2025.
- Quarterly Assets fell 16.54% year-over-year to $29.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.9 million (down 16.54% YoY) and the FY2025 annual result came in at $29.9 million, down 16.54% from the prior year.
- Assets slipped to $29.9 million in Q4 2025 per SLGL's latest filing, from $34.6 million in the prior quarter.
- Across five years, Assets topped out at $69.2 million in Q4 2021 and bottomed at $27.1 million in Q1 2025.
- The 5-year median for Assets is $46.5 million (2021), against an average of $46.1 million.
- The widest annual swing landed in 2021, when Assets plunged 37.82%; it then increased 18.49% in 2022.
- Tracing SLGL's Assets over 5 years: stood at $69.2 million in 2021, then sank by 32.61% to $46.6 million in 2022, then declined by 2.88% to $45.3 million in 2023, then decreased by 20.85% to $35.8 million in 2024, then dropped by 16.54% to $29.9 million in 2025.
- Per Business Quant, the three latest SLGL Assets figures stand at $29.9 million (Q4 2025), $34.6 million (Q3 2025), and $39.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 29.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.92 Mn |
| Sep 30, 2025 | 34.59 Mn |
| Jun 30, 2025 | 39.31 Mn |
| Mar 31, 2025 | 27.06 Mn |
| Dec 31, 2024 | 35.85 Mn |
| Sep 30, 2024 | 42.98 Mn |
| Jun 30, 2024 | 42.01 Mn |
| Mar 31, 2024 | 39.91 Mn |
| Dec 31, 2023 | 45.29 Mn |
| Sep 30, 2023 | 49.86 Mn |
| Jun 30, 2023 | 55.10 Mn |
| Mar 31, 2023 | 49.04 Mn |
| Dec 31, 2022 | 46.63 Mn |
| Sep 30, 2022 | 51.29 Mn |
| Jun 30, 2022 | 54.98 Mn |
| Mar 31, 2022 | 56.06 Mn |
| Dec 31, 2021 | 69.19 Mn |
| Sep 30, 2021 | 52.83 Mn |
| Jun 30, 2021 | 46.41 Mn |
| Mar 31, 2021 | 53.61 Mn |
| Dec 31, 2020 | 59.16 Mn |
| Sep 30, 2020 | 66.34 Mn |
| Jun 30, 2020 | 74.63 Mn |
| Mar 31, 2020 | 76.82 Mn |
| Dec 31, 2019 | 61.30 Mn |
| Sep 30, 2019 | 67.88 Mn |
| Jun 30, 2019 | 63.38 Mn |
| Mar 31, 2019 | 67.99 Mn |
| Dec 31, 2018 | 69.68 Mn |
| Sep 30, 2018 | 80.64 Mn |
| Jun 30, 2018 | 86.36 Mn |
| Mar 31, 2018 | 89.94 Mn |
| Dec 31, 2017 | 15.32 Mn |
| Dec 31, 2016 | 10.99 Mn |